1. Cell Cycle/DNA Damage
    Cytoskeleton
    Membrane Transporter/Ion Channel
    Neuronal Signaling
  2. Microtubule/Tubulin
    nAChR

Vinblastine 

Cat. No.: HY-17418 Purity: >98.0%
Data Sheet SDS Handling Instructions

Vinblastine is a cytotoxic alkaloid used against various cancer types. Vinblastine inhibits the formation of microtubule and suppresses nAChR with an IC50 of 8.9 μM.

For research use only. We do not sell to patients.
Vinblastine Chemical Structure

Vinblastine Chemical Structure

CAS No. : 865-21-4

Size Price Stock Quantity
10 mM * 1 mL in DMSO $55 In-stock
10 mg $50 In-stock
50 mg $120 In-stock
100 mg $200 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Other Forms of Vinblastine:

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Vinblastine is a cytotoxic alkaloid used against various cancer types. Vinblastine inhibits the formation of microtubule and suppresses nAChR with an IC50 of 8.9 μM.

IC50 & Target

IC50: 8.9 μM(nAChR)[1]

In Vitro

Vinblastine does not depolymerize spindle microtubules, yet it powerfully blocks mitosis (for example, IC50 0.8 nM in HeLa cells) and cells die by apoptosis[2]. In NB4 cells, vinblastine produces alteration of p53 and DNA fragmentation. Vinblastine treatment has an antiproliferative effect via the induction of apoptosis producing Bax/Bcl-2 imbalance. Vinblastine treatment suppresses NFκB expression and depresses NFκB-DNA binding activity while maintaining JNK activation that subsequently results in apoptotic response through caspase-dependent pathway[3]. Vinblastine is found to trigger apoptosis as evidenced by the loss of mitochondrial membrane potential, the release of both cytochrome c and apoptosis inducing factor, activation of caspase-9 and 3, and cleavage of Poly (ADP-ribose)-Polymerase[4].

In Vivo

Vinblastine is a widely used anticancer drug with undesired side effects. Its conjugation with carrier molecules could be an efficient strategy to reduce these side effects[5].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01135563 The Hospital for Sick Children|Solving Kids’ Cancer Solid Tumors|Central Nervous System Tumors April 2010 Phase 1
NCT00575796 The Hospital for Sick Children|Pediatric Oncology Group of Ontario|Paediatric Oncology Institutions of the Canadian Paediatric Brain Tumour Program Glioma October 2007 Phase 2
NCT00213278 The Hospital for Sick Children|Ontario Cancer Research Network Glioma January 2002 Phase 2
NCT01887522 Gustave Roussy, Cancer Campus, Grand Paris|Innovative Therapies For Children with Cancer Consortium Refractory Low-grade Gliomas|Recurrent Low-grade Gliomas June 2016 Phase 2
NCT02670707 Baylor College of Medicine|Texas Children's Hospital Langerhans Cell Histiocytosis March 2016 Phase 3
NCT00352495 Children's Oncology Group|National Cancer Institute (NCI) Brain and Central Nervous System Tumors|Neurofibromatosis Type 1 June 2006 Phase 1
NCT02840409 The Hospital for Sick Children|Hoffmann-La Roche Low Grade Glioma August 2016 Phase 2
NCT02343718 Canadian Cancer Trials Group|Pfizer Recurrent Lymphoma|Refractory Lymphoma|Solid Tumours|Central Nervous System June 2, 2015 Phase 1
NCT01884922 Gustave Roussy, Cancer Campus, Grand Paris Refractory Low-grade Gliomas|Recurrent Low-grade Gliomas May 2013 Phase 1
NCT00215046 Boston Children’s Hospital|Dana-Farber Cancer Institute Intraluminal Pulmonary Vein Stenosis March 2000 Phase 2
NCT00003019 Children's Oncology Group|National Cancer Institute (NCI)|Children's Cancer Group Desmoid Tumor August 1997 Phase 2
NCT00885534 Memorial Sloan Kettering Cancer Center Melanoma|Skin Cancer April 2009 Phase 2
NCT00030264 Children's Hospital of Philadelphia Neurofibromatosis Type 1|Precancerous Condition February 2001 Phase 2
NCT02414568 The Lymphoma Academic Research Organisation Classical Hodgkin Lymphoma July 2015 Phase 2
NCT01196416 National Cancer Institute (NCI) Recurrent Melanoma|Stage IV Skin Melanoma August 2010 Phase 1|Phase 2
NCT03092986 Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh Carcinoma, Non-Small-Cell Lung April 2017 Phase 3
NCT02979522 Millennium Pharmaceuticals, Inc.|Takeda Hodgkin Disease July 18, 2017 Phase 1
NCT01542255 Dartmouth-Hitchcock Medical Center Metastatic Melanoma June 2010 Phase 2
NCT00001570 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Kidney Neoplasms|Neoplasm Metastasis February 1997 Phase 1
NCT00059839 Children's Oncology Group|National Cancer Institute (NCI) Lymphoma November 2003 Phase 3
NCT00002495 Southwest Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B Lymphoma September 1992 Phase 3
NCT00003181 Hope Cancer Institute, Inc.|National Cancer Institute (NCI) Kidney Cancer May 1997 Phase 2
NCT00072215 Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Extragonadal Germ Cell Tumor|Testicular Germ Cell Tumor April 2004 Phase 3
NCT01876082 Institut Bergonié Progressive Desmoids Tumors July 2012 Phase 2
NCT01285817 Assistance Publique Hopitaux De Marseille Solid Tumours. November 2010 Phase 2
NCT00086801 Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Lymphoma May 2004 Phase 2
NCT01812369 University Hospital, Rouen Bladder Cancer March 2013 Phase 3
NCT00506155 M.D. Anderson Cancer Center|Genentech, Inc. Bladder Cancer June 2007 Phase 2
NCT01534078 Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute|H. Lee Moffitt Cancer Center and Research Institute|Seattle Genetics, Inc. Hodgkin Lymphoma March 2012 Phase 2
NCT00061893 Children's Oncology Group|National Cancer Institute (NCI) Sarcoma April 2004 Phase 2
NCT00635726 Hellenic Oncology Research Group|University Hospital of Crete Bladder Cancer February 2008 Phase 2
NCT00003084 M.D. Anderson Cancer Center|National Cancer Institute (NCI) Prostate Cancer December 1997 Phase 2
NCT01088750 Christine Mauz-Körholz|Deutsche Krebshilfe e.V., Bonn (Germany)|Euronet Worldwide|Martin-Luther-Universität Halle-Wittenberg Lymphoma November 2009 Phase 4
NCT01476410 Northwestern University|Robert H. Lurie Cancer Center|Seattle Genetics, Inc. Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Stage II Adult Hodgkin Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage IV Adult Hodgkin Lymphoma November 2011 Phase 2
NCT01639521 University of Southern California|National Cancer Institute (NCI) Anterior Urethral Cancer|Localized Transitional Cell Cancer of the Renal Pelvis and Ureter|Posterior Urethral Cancer|Recurrent Bladder Cancer|Recurrent Urethral Cancer|Regional Transitional Cell Cancer of the Renal Pelvis and Ureter|Stage III Bladder Cancer|Transitional Cell Carcinoma of the Bladder|Ureter Cancer|Urethral Cancer Associated With Invasive Bladder Cancer May 2013 Phase 2
NCT02710734 Fox Chase Cancer Center Urothelial Carcinoma of the Bladder February 2016 Phase 2
NCT00512980 University of Cologne Hodgkin Lymphoma August 2008 Phase 2
NCT00498979 Case Comprehensive Cancer Center|National Cancer Institute (NCI) Stage IV Melanoma May 2007 Phase 1
NCT00006237 Southwest Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Cancer and Leukemia Group B|Children's Oncology Group Melanoma (Skin) August 2000 Phase 3
NCT00079105 Newcastle-upon-Tyne Hospitals NHS Trust Lymphoma January 2004 Phase 2
NCT00516750 Kyoto University|National Cancer Institute (NCI) Bladder Cancer July 2007 Phase 2
NCT02412670 ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group Localized Urothelial Carcinoma of the Renal Pelvis and Ureter|Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter|Regional Urothelial Carcinoma of the Renal Pelvis and Ureter April 2015 Phase 2
NCT02298257 The Lymphoma Academic Research Organisation HIV Infection|HIV-associated Hodgkin Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage IV Adult Hodgkin Lymphoma June 2015 Phase 2
NCT01056679 University of Cologne Hodgkin Lymphoma April 2010 Phase 1
NCT00654732 M.D. Anderson Cancer Center|Genentech, Inc. Hodgkin Lymphoma March 2008 Phase 2
NCT00504504 M.D. Anderson Cancer Center|Genentech, Inc. Lymphoma March 2001 Phase 2
NCT00002882 M.D. Anderson Cancer Center|National Cancer Institute (NCI) Melanoma|Skin Cancer November 1995 Phase 3
NCT00808639 Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Amgen Bladder Cancer|Muscle-invasive Bladder Cancer December 2008 Phase 2
NCT00147875 University of Cologne|German Hodgkin's Lymphoma Study Group|Eli Lilly and Company Hodgkin's Disease March 2004 Phase 1|Phase 2
NCT00005047 Southwest Oncology Group|National Cancer Institute (NCI)|NCIC Clinical Trials Group|University of Southern California Bladder Cancer August 1997 Phase 3
NCT01712490 Millennium Pharmaceuticals, Inc.|Seattle Genetics, Inc.|Takeda Hodgkin Lymphoma November 2012 Phase 3
NCT00488605 University of New Mexico Leukemia February 2004 Phase 3
NCT00014274 European Organisation for Research and Treatment of Cancer - EORTC Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer January 2001 Phase 2|Phase 3
NCT02177695 Southwest Oncology Group|National Cancer Institute (NCI) Bladder Cancer July 2014 Phase 2
NCT02292979 The Lymphoma Academic Research Organisation|Millennium Pharmaceuticals, Inc. Hodgkin Lymphoma March 2015 Phase 2
NCT00520403 Hoffmann-La Roche Renal Cell Cancer September 2007 Phase 2
NCT01771107 National Cancer Institute (NCI) AIDS-Related Hodgkin Lymphoma|Classical Hodgkin Lymphoma|HIV Infection|Stage II Hodgkin Lymphoma|Stage IIA Hodgkin Lymphoma|Stage IIB Hodgkin Lymphoma|Stage III Hodgkin Lymphoma|Stage IIIA Hodgkin Lymphoma|Stage IIIB Hodgkin Lymphoma|Stage IV Hodgkin Lymphoma|Stage IVA Hodgkin Lymphoma|Stage IVB Hodgkin Lymphoma March 7, 2013 Phase 1|Phase 2
NCT00003027 Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Southwest Oncology Group|Cancer and Leukemia Group B Melanoma (Skin) October 1997 Phase 3
NCT00003376 Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer September 1998 Phase 3
NCT01134861 Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology Lung Cancer July 1994 Phase 3
NCT00417014 Children's Cancer and Leukaemia Group|National Cancer Institute (NCI) Lymphoma
NCT02181738 Bristol-Myers Squibb Hodgkin Disease July 2014 Phase 2
NCT00000626 National Institute of Allergy and Infectious Diseases (NIAID)|Amgen HIV Infections|Hodgkin's Disease Phase 2
NCT01468740 Harlachinger Krebshilfe e.V.|Deutsche AIDS Gesellschaft e.V. HIV-associated Hodgkin Lymphoma March 2004 Phase 2
NCT00352027 St. Jude Children's Research Hospital Hodgkin's Lymphoma July 2006 Phase 2
NCT00225173 Stanford University|National Cancer Institute (NCI) Hodgkin Disease October 2001 Phase 2
NCT00186875 St. Jude Children's Research Hospital Acute Lymphoblastic Leukemia|Lymphoma, Lymphoblastic November 2003 Phase 2
NCT00004209 Cancer Research UK|National Cancer Institute (NCI) Lung Cancer May 1998 Phase 3
NCT00006212 Center for Molecular Medicine|National Cancer Institute (NCI) Lung Cancer November 1999 Phase 1
NCT01060904 Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc. Disease, Hodgkin January 2010 Phase 1
NCT00038558 M.D. Anderson Cancer Center Hodgkin Disease November 2001 Phase 3
NCT03004833 University of Cologne Classical Hodgkin Lymphoma February 21, 2017 Phase 2
NCT01251107 Fondazione Michelangelo Hodgkin Lymphoma March 2000 Phase 3
NCT03159897 Fondazione Italiana Linfomi ONLUS Hodgkin Lymphoma June 2017 Phase 3
NCT00003389 Eastern Cooperative Oncology Group|National Cancer Institute (NCI) Lymphoma April 1999 Phase 3
NCT01868451 Memorial Sloan Kettering Cancer Center|Seattle Genetics, Inc.|University of Rochester|City of Hope Medical Center|Stanford University Hodgkin Lymphoma May 2013
NCT01700946 St. Jude Children's Research Hospital|Cookies for Kids' Cancer|Assisi Foundation Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood B-Lymphoblastic Lymphoma April 15, 2013 Phase 2
NCT03033914 Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb|M.D. Anderson Cancer Center|City of Hope Medical Center Hodgkin Lymphoma January 25, 2017 Phase 1
NCT00002855 M.D. Anderson Cancer Center|National Cancer Institute (NCI) Prostate Cancer August 1996 Phase 3
NCT00369681 Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI) Lymphoma May 2006 Phase 2
NCT00005090 Southwest Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Cancer and Leukemia Group B Lymphoma April 2000 Phase 3
NCT03226249 Northwestern University|National Cancer Institute (NCI) Classical Hodgkin Lymphoma|Lymphocyte-Depleted Classical Hodgkin Lymphoma|Lymphocyte-Rich Classical Hodgkin Lymphoma|Mixed Cellularity Classical Hodgkin Lymphoma|Nodular Sclerosis Classical Hodgkin Lymphoma August 15, 2017 Phase 2
NCT01148446 Fondazione Italiana Linfomi ONLUS Elderly Patients (>65 Years)|Diffuse Large B Cell Lymphoma (DLBCL) January 2003 Phase 3
NCT00030459 British Thoracic Society|Medical Research Council|National Cancer Institute (NCI) Malignant Mesothelioma November 2000 Phase 2
NCT00187070 St. Jude Children's Research Hospital Lymphoma, Large Cell|Lymphoma, Non-Hodgkin December 1997
NCT00024167 M.D. Anderson Cancer Center|National Cancer Institute (NCI) Prostate Cancer April 2002 Phase 3
NCT00276757 Histiocyte Society|National Cancer Institute (NCI) Childhood Langerhans Cell Histiocytosis April 2001
NCT02205762 North American Consortium for Histiocytosis|Histiocyte Society Langerhans Cell Histiocytosis July 2014 Phase 2|Phase 3
NCT00822120 Southwest Oncology Group|National Cancer Institute (NCI) Lymphoma|Nonneoplastic Condition July 2009 Phase 2
NCT00678327 Cancer Research UK|National Cancer Institute (NCI) Lymphoma August 2008 Phase 3
NCT00002561 NCIC Clinical Trials Group|Eastern Cooperative Oncology Group|Canadian Cancer Trials Group Hodgkin Lymphoma January 1994 Phase 3
NCT01356680 University of Cologne Hodgkin Lymphoma December 2011 Phase 3
NCT00265018 University of Cologne Hodgkin´s Lymphoma May 1998 Phase 3
NCT00028756 European Organisation for Research and Treatment of Cancer - EORTC|National Cancer Institute (NCI)|Groupe D'Etude des Tumeurs Uro-Genitales|Institute of Cancer Research, United Kingdom|NCIC Clinical Trials Group|Arbeitsgemeinschaft Urologische Onkologie Stage III Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder October 2001 Phase 3
NCT00004010 Children's Oncology Group|National Cancer Institute (NCI) Lymphoma October 1999 Phase 2
NCT00002823 Gustave Roussy, Cancer Campus, Grand Paris Lung Cancer February 1995 Phase 3
NCT00002919 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Bladder Cancer November 1996 Phase 2
NCT00724100 Albany Molecular Research, Inc.|Westat Cancer September 2008 Phase 1
NCT00187057 St. Jude Children's Research Hospital|Children's Hospital of Philadelphia|National Cancer Institute (NCI) Ataxia-Telangiectasia September 2002
NCT00003640 European Organisation for Research and Treatment of Cancer - EORTC Bladder Cancer September 1998 Phase 2
NCT00005584 European Organisation for Research and Treatment of Cancer - EORTC|Lymphoma Study Association|UNICANCER Lymphoma October 1998 Phase 3
NCT00002887 Ottawa Regional Cancer Centre|National Cancer Institute (NCI) Lung Cancer July 1995 Phase 1
NCT00083083 American College of Radiology Imaging Network|National Cancer Institute (NCI)|Radiation Therapy Oncology Group Lung Cancer March 2005 Phase 2
NCT00004887 The Christie NHS Foundation Trust|National Cancer Institute (NCI) Lung Cancer January 1999 Phase 3
NCT00003701 Eastern Cooperative Oncology Group|National Cancer Institute (NCI) Bladder Cancer|Urethral Cancer March 1999 Phase 3
NCT00274950 Children's Cancer and Leukaemia Group|National Cancer Institute (NCI) Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Ovarian Cancer May 2005 Phase 3
NCT00002566 UNICANCER|National Cancer Institute (NCI) Extragonadal Germ Cell Tumor|Testicular Germ Cell Tumor February 1994 Phase 3
NCT00264953 University of Cologne Hodgkin´s Lymphoma May 1998 Phase 3
NCT00002715 Stanford University|National Cancer Institute (NCI) Lymphoma April 1989 Phase 2
NCT00003240 National Cancer Institute (NCI) Lung Cancer October 1995 Phase 3
NCT01132807 Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Lymphoma May 2010 Phase 2
NCT00398554 Christine Mauz-Körholz|Martin-Luther-Universität Halle-Wittenberg Lymphoma June 2005 Phase 2
NCT00379041 European Organisation for Research and Treatment of Cancer - EORTC Lymphoma September 1993 Phase 3
NCT00002462 European Organisation for Research and Treatment of Cancer - EORTC Lymphoma September 1989 Phase 3
NCT00030654 Radiation Therapy Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Cancer and Leukemia Group B|Southwest Oncology Group|NRG Oncology Prostate Cancer October 2002 Phase 3
NCT00416377 Children's Cancer and Leukaemia Group|National Cancer Institute (NCI) Lymphoma
NCT00317408 European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma|National Cancer Institute (NCI) Lymphoma April 2004
NCT00049595 European Organisation for Research and Treatment of Cancer - EORTC|Lymphoma Trials Office|Lymphoma Study Association|Grup per l'Estudi dels Limfomes de Catalunya i Balears|NCIC Clinical Trials Group|Australasian Leukaemia and Lymphoma Group|Nordic Lymphoma Group Lymphoma August 2002 Phase 3
NCT00041210 Mount Vernon Cancer Centre at Mount Vernon Hospital|National Cancer Institute (NCI) Lymphoma October 2001 Phase 3
NCT00025064 Children's Cancer and Leukaemia Group|National Cancer Institute (NCI) Lymphoma January 2000 Phase 2
NCT00006455 Gustave Roussy, Cancer Campus, Grand Paris|National Cancer Institute (NCI) Lymphoma December 1999 Phase 3
NCT00003421 Medical Research Council|National Cancer Institute (NCI) Lymphoma June 1998 Phase 3
NCT00003262 Centro di Riferimento Oncologico - Aviano|National Cancer Institute (NCI) Lymphoma May 1997 Phase 2
NCT00003209 European Organisation for Research and Treatment of Cancer - EORTC|Medical Research Council Cervical Cancer December 1997 Phase 3
NCT00003159 Medical Research Council|European Organisation for Research and Treatment of Cancer - EORTC|National Cancer Institute (NCI) Lung Cancer August 1997 Phase 3
NCT00002714 Stanford University|National Cancer Institute (NCI) Lymphoma April 1995 Phase 2
View MoreCollapse
References
M.Wt

810.97

Formula

C₄₆H₅₈N₄O₉

CAS No.

865-21-4

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 42 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Purity: >98.0%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Vinblastine
Cat. No.:
HY-17418
Quantity: